Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid pain medications that aim to effectively inhibit pain transmission without the risk of addiction. The company's lead product candidates, LTG-001 and LTG-321, are Na v 1.8 inhibitors targeting musculoskeletal pain and chronic pain, respectively, with a particular focus on areas of significant unmet need.
Not disclosed in the provided filing text.
Not disclosed in the provided filing text.
This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.
Latigo Biotherapeutics, Inc.'s offering is currently expected on NASDAQ. The expected date is Aug 6, 2026. Shares are expected to be offered at $16.00 – $18.00, with 16.0M shares on offer, for a total offer size of $313M. The proposed ticker is LTGO. Underwriters on the deal include Goldman Sachs & Co. LLC, Jefferies LLC, Leerink Partners LLC, Guggenheim Securities, LLC. Latigo Biotherapeutics, Inc. is headquartered in United States and incorporated in DE. It is classified under Pharmaceutical Preparations.
Latigo Biotherapeutics, Inc. has filed 4 times, starting with a S1/A on Aug 3, 2026.
The dates below are calculated from widely-used industry conventions, not from this offering's own disclosed terms — DiscoverIPO does not have a structured source for the actual figures. Treat them as reference points, not confirmed dates.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Latigo Biotherapeutics, Inc..
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/latigo-biotherapeutics" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Latigo Biotherapeutics, Inc. — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/latigo-biotherapeutics?theme=light as the src instead.
https://www.discoveripo.com/ipo/latigo-biotherapeutics/opengraph-image
Latigo Biotherapeutics, Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/latigo-biotherapeutics?utm_source=embed&utm_medium=text&utm_campaign=latigo-biotherapeutics
Get emailed when Latigo Biotherapeutics, Inc.'s terms, price, or expected date change — no weekly noise, just this company.
Latigo Biotherapeutics, Inc. is expected to list on Aug 6, 2026.
Latigo Biotherapeutics, Inc. is listing on NASDAQ.
Latigo Biotherapeutics, Inc.'s offering is expected to raise $313M.
Latigo Biotherapeutics, Inc.'s proposed ticker is LTGO.
New York Stock Exchange listings data. Retrieved Aug 3, 2026.
View the original filing on NYSE →How this offering's SEC filings changed over time. Only SEC-sourced filings carry a full amendment history to compare; other regulators publish a single filing with no prior version to diff against.
Initial filing.
No tracked deal terms changed in this amendment.
Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy